The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability
Open accessAbstract
Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The knockdown of HRAS and NRAS sensitized KRAS-wildtype cell lines to BI-2865.
“The knockdown of HRAS and NRAS sensitized KRAS-wildtype cell lines to BI-2865 [63].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [63]
Citations
Cites
Ciereszko, I., Johansson, H., Hurry, V., & Kleczkowski, L. A. (2001) · Planta · doi:10.1007/s004250000424 · Cited by 152
Coordinate Regulation of Sugar Flux and Translation by PAS Kinase
Rutter, J. P., Probst, B., & McKnight, S. L. (2002) · Cell · doi:10.1016/s0092-8674(02)00974-1 · Cited by 110
Role of N‐glycosylation in EGFR ectodomain ligand binding
Irani, M. A., Kannan, S., & Verma, C. S. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25314 · Cited by 84
Perenthaler, E., Nikoncuk, A., Yousefi, S., Berdowski, W. M., Alsagob, M., Čapo, I., van der Linde, H. C., van den Berg, P., Jacobs, E. H., Putar, D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02109-6 · Cited by 67
Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103592118 · Cited by 55
Self-citationFuehring, J. I., Cramer, J., Schneider, J. R., Baruch, P., Gerardy‐Schahn, R., & Fedorov, R. (2015) · Scientific Reports · doi:10.1038/srep09618 · Cited by 46
Manrow, R. E., & Dottin, R. P. (1982) · Analytical Biochemistry · doi:10.1016/0003-2697(82)90334-7 · Cited by 26
Zeng, C., Xing, W., & Liu, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28515 · Cited by 25
Wang, X., Ju, L., Fan, J., Zhu, Y., Liu, X., Zhu, K., Wu, M., & Li, L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.06.013 · Cited by 20
Durrant, C., Fuehring, J. I., Willemetz, A., Chrétien, D., Sala, G., Ghidoni, R., Katz, A., Rötig, A., Thelestam, M., Ermonval, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062028 · Cited by 14
Flagged first, then by citations
Research works printed but not linked: 1
- Perenthaler E, Acta Neuropathol.
Cited by
Sorted by citations
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“Additionally, a pan-KRAS CYPA-recruiting compound, RMC-6236, is currently undergoing clinical trial [64].”
BackgroundSelf-citationMahendran, R., Lim, S. K., Ong, K. C., Chua, K. H., & Chai, H. C. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103655 · Cited by 5
Polysaccharides as therapeutic vehicles in pancreatic cancer
Kumari, S., Peela, S., Nagaraju, G. P., & Srilatha, M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104320 · Cited by 5
Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function
Lam, D., Arroyo, B., Liberchuk, A. N., Das, J., Ash, L. J., Khan, K. M., Mondal, J., & Wolfe, A. L. (2026) · Cancers · doi:10.3390/cancers18030474 · Cited by 4
Self-citationGuo, H., Zhang, L., Hu, T., Liu, P., Hu, B., Gong, Y., Hou, R., & Wu, Z. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25020 · Cited by 2
Soares, R. B., Pinto, J., Amaro, F., Manguinhas, R., Gil, N., Rosell, R., Batinic̈‐Haberle, I., Fernandes, A. S., Oliveira, N., & de Pinho, P. G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116424 · Cited by 2
Gong, R., Qiu, M., Liu, Y., Cao, J., Zhou, Z., Lin, Q., Jiang, Y., Liang, X., Wei, Y., Wen, Q., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s492516 · Cited by 2
Ye, Y., Zeng, Y., Huang, S., Zhu, C., & Wang, Q. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s506706
Clustering of host N-glycans licenses Toxoplasma rhoptry dischargePreprint
Valleau, D., Goyal, M., Roberts, J. M., Male, F., Ward, G. E., & Lourido, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682961
Zhang, X., Zheng, Z., Chang, Y. H., Wang, Z., Han, J., & He, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-27055-0
Zhou, Y., Song, N., Hu, H., Wang, Y., Zhao, Z., Sun, C., Xie, S., Yu, A., Xu, F., Li, D., et al. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c07617
Clustering of host N-glycans by the microneme MIC1/4/6 complex licenses Toxoplasma rhoptry discharge
Valleau, D., Goyal, M., Roberts, J. M., Male, F., Ward, G. E., & Lourido, S. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00911-z
Metadata
- Authors
- Kim, S., Wolfe, A., & Kim, S. E.
- Affiliations
- Department of Biosystems and Biomedical Sciences, College of Health Sciences, Korea University, Seoul, Republic of Korea
- The Graduate Center, CUNY (US)
- Korea University (KR)
- Corresponding author
- Wolfe, Andrew
- Kim, Sung Eun
- Venue
- Molecular & Cellular Oncology
- Publisher
- Informa UK Limited
- Published
- 2021-10-27
- Volume
- 8
- Issue
- 6
- Pages
- 1990676-1990676
- ISSN
- 2372-3548 (ISSN-L)
- 2372-3556
- PMC
- PMC8997258
- OpenAlex
- W3209168692
- Cited by
- 12
- References
- 10
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular & Cellular Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Damon Runyon Cancer Research Foundation (DRG-2214-15)
- National Cancer Institute of the NIH (K99CA226363 and R00CA226363 (to A.L.W.))
- the National Research Foundation of Korea (NRF-2020R1C1C1013220 (to S.E.K.))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- UGP2, tumor metabolic reprogramming, therapeutic vulnerabilities, UDP-glucose, cancer metabolism, tumor growth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
